Zynerba Pharmaceuticals (ZYNE)

[barnyarddog]

Zygel™ (ZYN002 CBD Gel) is the first and only pharmaceutically-manufactured CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. Zygel is being developed for patients suffering from neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD) in pediatric patients, 22q, and certain rare refractory epilepsies called DEEs. The U.S. Food and Drug Administration has granted Orphan Drug designation to Zynerba for the use of CBD for treatment of patients with FXS.


80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
484.581.7505
https://zynerba.com/our-focus/why-pharmaceutical-manufacturing/